|
WO2021029746A2
|
|
Anti-tie2 antibody and use thereof
|
|
WO2020175886A1
|
|
Anti-ang2 antibody and use thereof
|
|
US2021009695A1
|
|
Anti-vegfr-2 antibody
|
|
EP3699193A2
|
|
Anti-vista antibody and use thereof
|
|
KR20190078771A
|
|
Anti-PD-L1 Antibody and Use Thereof
|
|
KR20170087439A
|
|
Novel Antibody Binding to EGFRvlll and Composition Comprising the Same
|
|
KR20180132401A
|
|
Composition for treating or preventing cancer
|
|
AU2014412643A1
|
|
Novel EGFRvIII antibody and composition comprising same
|
|
KR20160062535A
|
|
Novel Antibody Binding to EGFRvlll and Composition Comprising the Same
|
|
WO2016060297A1
|
|
Dual-target antibody having binding ability to vegfr-2 and c-met
|
|
KR20160044774A
|
|
Double Target Antibody having Binding ability for VEGFR-2 and c-Met
|
|
KR20160017918A
|
|
c-Met Specific Human Antibody and Method for Manufacturing the Same
|
|
AU2013348570A1
|
|
Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same
|
|
WO2012161372A1
|
|
Double-target antibody fused with a peptide and use of same
|
|
KR20100125033A
|
|
Bispecific antibody having a novel form and use thereof
|
